|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 CNY | 0.00% |
|
-2.94% | -18.66% |
Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported revenue was CNY 27,600.24 million compared to CNY 22,922.96 million a year ago. Net income was CNY 176.14 million compared to CNY 314.81 million a year ago.
Basic earnings per share from continuing operations was CNY 0.036 compared to CNY 0.064 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.66% | 1.58B | |
| +14.34% | 79.29B | |
| +10.04% | 51.58B | |
| +4.15% | 48.51B | |
| +21.52% | 46.18B | |
| +14.52% | 42.35B | |
| +27.72% | 40.27B | |
| -0.31% | 31.18B | |
| -1.41% | 29.34B | |
| -9.63% | 27.02B |
HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD. 
